Compare ARTL & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTL | RDHL |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Israel |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.2M |
| IPO Year | N/A | 2012 |
| Metric | ARTL | RDHL |
|---|---|---|
| Price | $0.88 | $0.73 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 166.5K | 63.6K |
| Earning Date | 05-13-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.63 |
| 52 Week High | $19.91 | $2.79 |
| Indicator | ARTL | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.26 | 46.33 |
| Support Level | N/A | $0.71 |
| Resistance Level | $1.24 | $0.91 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 0.00 | 62.50 |
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.